abstract
- SOURCE CITATION: Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142:734-47. 32795086.
Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD
Academic Article
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- January 2021
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Benzhydryl Compounds (MeSH)
- Diabetes Mellitus, Type 2 (MeSH)
- Glucosides (MeSH)
- Humans (MeSH)
- Kidney (MeSH)
- Peripheral Arterial Disease (MeSH)
- Sodium-Glucose Transporter 2 Inhibitors (MeSH)
published in
- ACP journal club Journal